Researchers and medical experts expressed concerns about the safety of Pfizer's Celebrex and Bextra, linking them to potential heart problems similar to Vioxx.
The FDA faced criticism for not requiring thorough studies on Vioxx's risks earlier.
Merck's decision to withdraw Vioxx highlighted flaws in the drug safety monitoring system.
The FDA's hands-off approach towards drug companies was questioned, with calls for more stringent testing and monitoring.
Pfizer is investigating whether Bextra poses a similar heart attack risk, following Merck's Vioxx withdrawal.
Patients are advised to consult doctors for alternative pain relief options.
